Mylan to sell Gilead's branded drugs in India

Gilead Sciences, Inc. has partnered with Mylan Pharmaceuticals Private Limited - the Indian-based subsidiary of Mylan Inc. to sell exclusive branded medicine business in Indian market.

Under the agreement, Mylan will market and distribute in India medicines such as ®HIV medicines - Viread, Truvada® and the newer single tablet regimen Stribild., Mylan will also sell AmBisome, a treatment for life-threatening, systemic fungal infections.
 
“The appointment of Mylan as our branded medicine business partner in India is a result of their strong knowledge of the Indian healthcare system and demonstrated capabilities of supporting and distributing antiretroviral therapies,” said Gregg H. Alton, Gilead’s Executive Vice President of Corporate and Medical Affairs.

In addition to distributing branded Gilead medicines, Mylan will manage regulatory and pharmaco-vigilance activities (such as adverse event reporting) as well as broader medical education initiatives.

India is home to the world's third largest population of people with HIV/AIDS, with approximately 2.4 million people living with the disease.